Amyotrophic Lateral Sclerosis
Vision – Improve treatments and find cures for people with ALS
» Click on Image to View Program Booklet
» Click on Image to View Strategic Plan
» Click on Image to View Program Summary Sheet
» Click on Image to View Program Overview
Amyotrophic Lateral Sclerosis (ALS), also known as "Lou Gehrig's disease," is a degenerative neurological disorder without a cure. For reasons that are not well understood, the nerve cells in the brain and spinal cord that control voluntary muscle movement gradually deteriorate. ALS can be difficult to diagnose because the initial symptoms are both subtle and vague and can be attributed to a number of other conditions. Average life expectancy after diagnosis ranges between 3 to 5 years from the onset of symptoms. It is estimated that 5-10% of all ALS cases are inherited (familial disease) while the remaining 90-95% are sporadic, with unknown etiology and risk factors. There is currently no known cure or therapy to effectively halt the progression of ALS. Evidence from scientific research suggests a mutually inclusive relationship between ALS and military service, with a higher rate of incidence in the Veteran population, without any known reason(s) for this incidence.
The ALSRP is guided by a vision to improve treatments and find cures for people with ALS. Through its award mechanisms and funding recommendations, the ALSRP specifically supports impactful research to develop ALS treatments.
ALSRP Initiatives
Congressional Appropriations
- $229.4 million FY07, FY09-23
- $40 million
FY24
Funding
Summary
- 190 Awards in
FY07, FY09-22 - Recent Applications Recommended for Funding
Programmatic
Panels
Peer Review Participants
Related Videos
Matt Bellina
ALS Therapy Development Institute
A Consumer's Perspective: An Increased Sense of Urgency
News & Highlights
- Department of Defense Amyotrophic Lateral Sclerosis Research Program Anticipated Funding Opportunities for Fiscal Year 2025 (FY25)
- FY24 ALSRP Recommended for Funding List
- New brain-computer interface allows man with ALS to "speak" again (external link)
- FDA grants IND clearance for Spinogenix's ALS treatment trial (external link)
- Mapping a Path Forward: Patient Involvement throughout ALS Therapeutic Development and Clinical Research
- Prosetin in ALS patients (external link)
- Using Machine Learning for Drug Repurposing to Impact ALS Treatment
- The Therapeutic Potential of Metformin in ALS: Moving Through the ALSRP Pipeline from Therapeutic Development Award (TDA) to Pilot Clinical Trial Award (PCTA)
- Amyotrophic Lateral Sclerosis Research Program Recognized for Including Consumer Reviewers in Two-Tier Review System
- New Nerve-on-a-Chip System Could Revolutionize Therapeutic Development for ALS
- USC Stem Cell-led studies point the way to broadly effective treatments for ALS (external link)
- A Combined Cell and Gene Therapy Approach for Preserving Motor Neuron Function in ALS
- Research Resources
- ALSRP Program Summary Sheet
- More…
Vision
Improve treatments and find cures for people with ALS
Mission
Fund impactful research to develop ALS treatments
Last updated Tuesday, December 17, 2024